Abstract 399P
Background
Due to the lack of studies on unfit patients with gastric cancer (GC) who did not receive any aggressive cancer treatment—best supportive care (BSC) cases—their long-term prognosis remains unclear, especially for those harboring potentially curable disease (clinical stage [cStage] I–III). Therefore, clinicians sometimes have trouble answering unfit patients or their caregivers when asked questions such as “How long will I live without any anticancer treatment?”. Hence, we conducted this observational study to capture the real-world data of baseline characteristics, provided supportive care, and long-term outcomes for BSC cases.
Methods
Consecutive clinical records of patients with GC diagnosed at Steel Memorial Muroran Hospital (SMMH) from January 2017 to December 2021 were collected and analyzed. We conducted this study with the approval of the Institutional Review Board of SMMH (#J230103). The primary outcome of this study is overall survival (OS).
Results
Of 481 patients diagnosed with GC, 91 (18.9%) were BSC cases; their median age was 85 (range: 46–96) years, and 75.8% were male. BSC cases showed a very high risk of receiving aggressive cancer treatment with a median Age-Adjusted Charlson Comorbidity Index score of 7 and a G-8 score of 7. The median OS for all patients was 3.9 months (95% confidence interval [CI]: 3.0–5.4). The median OS was 12.4, 8.3, and 2.5 months for cStage I, II–III, and IV, respectively. Patients with potentially curable GC (cStage I–III) had significantly longer OS than those with incurable disease (cStage IV), with a hazard ratio for death of 0.29 (95% CI: 0.18–0.47, p<0.0001). The percentage of death by GC in a total number of deaths also increased with increasing stage. Pneumonia and heart failure were the most common cause of death among cases who died other than GC. After diagnosis, cStage I patients were more likely to prefer to stay where they had lived (nursing homes or their own house), while more advanced stage patients chose hospice.
Conclusions
The median OS of BSC cases in poor general condition was ∼1 year for cStage I, 8 months for cStage II–III, and < 3 months for cStage IV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Takada: Financial Interests, Personal, Invited Speaker: Eisai, Janssen, Chugai, Ono, Otsuka, Daiichi Sankyo, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract